The Saskatchewan Cancer Agency (SCA) announced the launch of a new treatment option for people with cervical cancer. The Interstitial High-Dose Rate Gynecological Brachytherapy (HDR) program is a targeted form of radiation therapy that is “the gold standard of care,” according to the SCA. The technique treats irregular sized tumours through precise, high dose radiation, while reducing radiation exposure to surrounding healthy tissue. Health Minister Jeremy Cockrill said providing care to Saskatchewan cancer patients close to home is a top priority for the government. “We are dedicated to driving healthcare innovation that enhances patient outcomes and improves quality of life for all residents,” he said in a news release from the province. More than 20 patients are expected to benefit from the program annually. “We’re excited to expand our treatment options and provide this safe, innovative and highly effective treatment for cervical cancer patients right here, where they’re close to their support networks,” said Dr. Jocelyn Moore, radiation oncologist with the SCA. The procedure is available in Saskatoon, with plans to expand to Regina. The program will be rolled out in three phases, with the first phase focusing on the introduction of hybrid therapy. This phase combines the standard applicator with additional interstitial needles for precision and effectiveness. The second and third phases will involve introducing different applicators to expand treatment options. Over 13,000 North American women are diagnosed with cervical cancer each year and more than 4,300 die from the disease.
|
